Equitec Specialists’s Ionis Pharmaceuticals IONS Stock Holding History

Equitec Specialists’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-73	Closed	-$4K	–	104
2017 Q4	$4K	Sell	73 -85	-54%	-$4.66K	﹤0.01%	101
2017 Q3	$8K	Hold	158	–	–	﹤0.01%	97
2017 Q2	$8K	Buy	+158	New	+$7.36K	﹤0.01%	100
2017 Q1	–	Sell	-3,958	Closed	-$178K	–	78
2016 Q4	$189K	Buy	+3,958	New	+$157K	0.05%	68

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Equitec Specialists's IONS Position: Q1 2018 in Review

Equitec Specialists sold out of Ionis Pharmaceuticals (IONS) in Q1 2018, closing a stake of 73 shares — an estimated $4K sold.

Equitec Specialists first reported a position in IONS in Q4 2016 and held it in 4 quarters. The position peaked at $189K in Q4 2016. 325 funds tracked by Wall St. Rank hold IONS as of Q1 2018.

Equitec Specialists reported no remaining Ionis Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Equitec Specialists sold 73 Ionis Pharmaceuticals shares in Q1 2018, an estimated $4K.
Equitec Specialists first reported a position in Ionis Pharmaceuticals in Q4 2016 and held it in 4 quarters.
Equitec Specialists's Ionis Pharmaceuticals position peaked at $189K in Q4 2016.
325 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2018.

Based on Equitec Specialists's 13F filing for Q1 2018, filed 23 May 2018.